Rekhi; Gurvinder Singh

Patent Applications and Registrations

Patent applications and USPTO patent grants for Rekhi; Gurvinder Singh.The latest application filed is for "controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride".

Company Profile

4.13.26

Rekhi; Gurvinder Singh - Suwanee GA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Abuse resistant pharmaceutical compositions Grant 10,960,000 - Rekhi , et al. March 30, 2	2021-03-30
Controlled Release Compositions Comprising A Combination Of Isosorbide Dinitrate And Hydralazine Hydrochloride App 20190380969 - Rekhi; Gurvinder Singh ; et al.	2019-12-19
Abuse Resistant Pharmaceutical Compositions App 20190167663 - Rekhi; Gurvinder Singh ; et al.	2019-06-06
Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride Grant 10,213,389 - Rekhi , et al. Feb	2019-02-26
Abuse resistant pharmaceutical compositions Grant 10,092,559 - Rekhi , et al. October 9, 2	2018-10-09
Abuse Resistant Pharmaceutical Compositions App 20170319576 - Rekhi; Gurvinder Singh ; et al.	2017-11-09
Controlled Release Compositions Comprising A Combination Of Isosorbide Dinitrate And Hydralazine Hydrochloride App 20170209381 - Rekhi; Gurvinder Singh ; et al.	2017-07-27
Abuse resistant pharmaceutical compositions Grant 9,713,611 - Rekhi , et al. July 25, 2	2017-07-25
Multiparticulate Modified Release Composition App 20170000783 - Devane; John G. ; et al.	2017-01-05
Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride Grant 9,463,166 - Rekhi , et al. October 11, 2	2016-10-11
Abuse Resistant Pharmaceutical Compositions App 20160279062 - Rekhi; Gurvinder Singh ; et al.	2016-09-29
Abuse resistant pharmaceutical compositions Grant 9,452,163 - Rekhi , et al. September 27, 2	2016-09-27
Controlled Release Compositions Comprising A Combination Of Isosorbide Dinitrate And Hydralazine Hydrochloride App 20160256400 - Rekhi; Gurvinder Singh ; et al.	2016-09-08
Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride Grant 9,308,177 - Rekhi , et al. April 12, 2	2016-04-12
Abuse resistant pharmaceutical compositions Grant 9,132,096 - Rekhi , et al. September 15, 2	2015-09-15
Controlled Release Compositions Comprising A Combination Of Isosorbide Dinitrate And Hydralazine Hydrochloride App 20150174077 - Rekhi; Gurvinder Singh ; et al.	2015-06-25
Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride Grant 8,992,973 - Rekhi , et al. March 31, 2	2015-03-31
Controlled Release Compositions Comprising A Combination Of Isosorbide Dinitrate And Hydralazine Hydrochloride App 20130004573 - Rekhi; Gurvinder Singh ; et al.	2013-01-03
Controlled Release Compositions Comprising A Combination Of Isosorbide Dinitrate And Hydralazine Hydrochloride App 20120100209 - Rekhi; Gurvinder Singh ; et al.	2012-04-26
Nanoparticulate and controlled release compositions comprising cefditoren Grant 8,119,163 - Devane , et al. February 21, 2	2012-02-21
Alcohol Resistant Enteric Pharmaceutical Compositions App 20110223244 - Liversidge; Gary ; et al.	2011-09-15
Nanoparticulate And Controlled Release Compositions Comprising Vitamin K2 App 20110064803 - Devane; John G. ; et al.	2011-03-17
Nanoparticulate and Controlled Release Compositions Comprising Aryl-Heterocyclic Compounds App 20110008435 - Devane; John G. ; et al.	2011-01-13
Nanoparticulate and controlled release compositions comprising nilvadipine App 20100247636 - Devane; John G. ; et al.	2010-09-30
Modified Release Famciclovir Compositions App 20100136106 - Liversidge; Gary ; et al.	2010-06-03
Modified Release Ticlopidine Compositions App 20090297597 - Liversidge; Gary ; et al.	2009-12-03
Nanoparticulate and Controlled Release Compositions Comprising Cefditoren App 20080279929 - Devane; John G. ; et al.	2008-11-13
Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone App 20080118556 - Devane; John G. ; et al.	2008-05-22
Compositions Comprising Nanoparticulate Naproxen And Controlled Release Hydrocodone App 20080113025 - Devane; John G. ; et al.	2008-05-15
Compositions Comprising Nanoparticulate Meloxicam And Controlled Release Hydrocodone App 20080102121 - Devane; John G. ; et al.	2008-05-01
Nanoparticulate and controlled release compositions comprising a cephalosporin App 20070160675 - Devane; John G. ; et al.	2007-07-12
Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride App 20070098791 - Rekhi; Gurvinder Singh ; et al.	2007-05-03
Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochrloride App 20070098796 - Rekhi; Gurvinder Singh ; et al.	2007-05-03
Multiparticulate modified release composition App 20060240105 - Devane; John G. ; et al.	2006-10-26
Multiparticulate modified release composition Grant 6,902,742 - Devane , et al. June 7, 2	2005-06-07
Multiparticulate modified release composition App 20040197405 - Devane, John G. ; et al.	2004-10-07
Multiparticulate modified release composition App 20030129237 - Devane, John G. ; et al.	2003-07-10

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.